PFE Pfizer Inc.

Price (delayed)

$38.17

Market cap

$212.03B

P/E Ratio

13.44

Dividend/share

$1.5

EPS

$2.84

Enterprise value

$262.17B

Sector: Healthcare
Industry: Drug Manufacturers - General
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Highlights

The price to earnings (P/E) is 33% lower than the 5-year quarterly average of 20.1 and 4% lower than the last 4 quarters average of 14.0
Pfizer's equity has increased by 11% YoY and by 3% QoQ
Pfizer's EPS has increased by 43% YoY but it has decreased by 2.7% from the previous quarter
Pfizer's net income has increased by 38% YoY but it has decreased by 3% QoQ
PFE's debt is up by 16% YoY
Pfizer's revenue has decreased by 6% YoY and by 2.1% QoQ

Key stats

What are the main financial stats of PFE
Market
Shares outstanding
5.55B
Market cap
$212.03B
Enterprise value
$262.17B
Valuations
Price to earnings (P/E)
13.44
Price to book (P/B)
3.26
Price to sales (P/S)
4.18
EV/EBIT
15.23
EV/EBITDA
11.45
EV/Sales
5.17
Earnings
Revenue
$50.66B
EBIT
$17.22B
EBITDA
$22.9B
Free cash flow
$11.55B
Per share
EPS
$2.84
Free cash flow per share
$2.08
Book value per share
$11.72
Revenue per share
$9.14
TBVPS
$13.23
Balance sheet
Total assets
$166.34B
Total liabilities
$101B
Debt
$52.29B
Equity
$65.03B
Working capital
$848M
Liquidity
Debt to equity
0.8
Current ratio
1.03
Quick ratio
0.6
Net debt/EBITDA
2.19
Margins
EBITDA margin
45.2%
Gross margin
79.9%
Net margin
31.2%
Operating margin
18.1%
Efficiency
Return on assets
9.6%
Return on equity
25%
Return on invested capital
20%
Return on capital employed
13%
Return on sales
34%
Dividend
Dividend yield
3.93%
DPS
$1.5
Payout ratio
52.8%

PFE stock price

How has the Pfizer stock price performed over time

Financial performance

How have Pfizer's revenue and profit performed over time
Revenue
$50.66B
Gross profit
$40.5B
Operating income
$9.15B
Net income
$15.79B
Gross margin
79.9%
Net margin
31.2%
PFE's net margin is up by 47% YoY
Pfizer's net income has increased by 38% YoY but it has decreased by 3% QoQ
The operating income has contracted by 24% YoY and by 4.7% from the previous quarter
The company's operating margin fell by 19% YoY and by 2.2% QoQ

Valuation

What is Pfizer stock price valuation
P/E
13.44
P/B
3.26
P/S
4.18
EV/EBIT
15.23
EV/EBITDA
11.45
EV/Sales
5.17
Pfizer's EPS has increased by 43% YoY but it has decreased by 2.7% from the previous quarter
The price to earnings (P/E) is 33% lower than the 5-year quarterly average of 20.1 and 4% lower than the last 4 quarters average of 14.0
Pfizer's equity has increased by 11% YoY and by 3% QoQ
Pfizer's revenue has decreased by 6% YoY and by 2.1% QoQ
PFE's P/S is 4.5% above its last 4 quarters average of 4.0 and 2% above its 5-year quarterly average of 4.1

Efficiency

How efficient is Pfizer business performance
Pfizer's ROS has soared by 52% YoY
The ROE rose by 44% YoY but it fell by 5% QoQ
Pfizer's ROA has increased by 35% YoY but it has decreased by 4% from the previous quarter
The company's return on invested capital rose by 27% YoY but it fell by 4.8% QoQ

Dividends

What is PFE's dividend history
DPS
$1.5
Dividend yield
3.93%
Payout ratio
52.8%
Recent dividends

Financial health

How did Pfizer financials performed over time
PFE's total assets is 65% greater than its total liabilities
The current ratio has contracted by 33% YoY but it has grown by 17% from the previous quarter
The quick ratio has grown by 20% from the previous quarter but it has contracted by 17% YoY
PFE's debt is 20% less than its equity
Pfizer's equity has increased by 11% YoY and by 3% QoQ
The debt to equity has grown by 3.9% YoY but it has contracted by 3.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.